{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=epoetin+alpha",
    "query": {
      "intervention": "epoetin alpha"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 12,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=epoetin+alpha&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-07T00:55:41.358Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00286182",
      "title": "Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anemia"
      ],
      "interventions": [
        {
          "name": "Erythropoietin alpha",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mathew S. Maurer",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2007-07",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2017-03-10",
      "last_synced_at": "2026-09-07T00:55:41.358Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00286182"
    },
    {
      "nct_id": "NCT02075970",
      "title": "Optimized Erythropoietin (EPO) Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neonatal Anemia"
      ],
      "interventions": [
        {
          "name": "Epoetin Alpha",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Iowa",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "2 Days",
        "sex": "ALL",
        "summary": "Up to 2 Days"
      },
      "enrollment_count": 33,
      "start_date": "2014-06",
      "completion_date": "2019-12",
      "has_results": true,
      "last_update_posted_date": "2026-07-23",
      "last_synced_at": "2026-09-07T00:55:41.358Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02075970"
    },
    {
      "nct_id": "NCT03682536",
      "title": "A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "Luspatercept",
          "type": "DRUG"
        },
        {
          "name": "Epoetin alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 363,
      "start_date": "2019-01-02",
      "completion_date": "2027-09-28",
      "has_results": true,
      "last_update_posted_date": "2024-11-20",
      "last_synced_at": "2026-09-07T00:55:41.358Z",
      "location_count": 25,
      "location_summary": "Berkeley, California • San Diego, California • Whittier, California + 22 more",
      "locations": [
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03682536"
    },
    {
      "nct_id": "NCT00842621",
      "title": "Long Term Effects of Erythrocyte Lysis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Sickle Cell Disease",
        "Hemolytic Anemia"
      ],
      "interventions": [
        {
          "name": "Clinical Evaluations",
          "type": "PROCEDURE"
        },
        {
          "name": "Laboratory Studies",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "5 Years and older"
      },
      "enrollment_count": 390,
      "start_date": "2009-03",
      "completion_date": "2016-06",
      "has_results": false,
      "last_update_posted_date": "2016-06-27",
      "last_synced_at": "2026-09-07T00:55:41.358Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00842621"
    },
    {
      "nct_id": "NCT03071861",
      "title": "Mild Encephalopathy in the Newborn Treated With Darbepoetin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neonatal Encephalopathy",
        "Hypoxic-Ischemic Encephalopathy Mild"
      ],
      "interventions": [
        {
          "name": "Darbepoetin Alfa",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of New Mexico",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Hour",
        "maximum_age": "24 Hours",
        "sex": "ALL",
        "summary": "1 Hour to 24 Hours"
      },
      "enrollment_count": 28,
      "start_date": "2017-12-01",
      "completion_date": "2022-09-01",
      "has_results": true,
      "last_update_posted_date": "2023-12-21",
      "last_synced_at": "2026-09-07T00:55:41.358Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03071861"
    },
    {
      "nct_id": "NCT00513240",
      "title": "Erythropoetin Neuroprotection for Neonatal Cardiac Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Congenital Heart Disease",
        "Hypoplastic Left Heart Syndrome",
        "Transposition of the Great Arteries",
        "Aortic Arch Hypoplasia or Interruption"
      ],
      "interventions": [
        {
          "name": "Erythropoetin",
          "type": "DRUG"
        },
        {
          "name": "Normal saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Day",
        "maximum_age": "30 Days",
        "sex": "ALL",
        "summary": "1 Day to 30 Days"
      },
      "enrollment_count": 62,
      "start_date": "2006-09",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2020-02-07",
      "last_synced_at": "2026-09-07T00:55:41.358Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00513240"
    },
    {
      "nct_id": "NCT00270478",
      "title": "Hydroxyurea and Erythropoietin to Treat Sickle Cell Anemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Chronic Kidney Disease",
        "Pulmonary Hypertension"
      ],
      "interventions": [
        {
          "name": "Erythropoietin and Hydroxyurea",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2005-12-21",
      "completion_date": "2009-08-31",
      "has_results": false,
      "last_update_posted_date": "2019-12-17",
      "last_synced_at": "2026-09-07T00:55:41.358Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00270478"
    },
    {
      "nct_id": "NCT02807558",
      "title": "A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Tamibarotene",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Daratumumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Syros Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 155,
      "start_date": "2016-09-20",
      "completion_date": "2023-01-25",
      "has_results": true,
      "last_update_posted_date": "2024-12-13",
      "last_synced_at": "2026-09-07T00:55:41.358Z",
      "location_count": 14,
      "location_summary": "Hartford, Connecticut • Miami, Florida • Iowa City, Iowa + 11 more",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02807558"
    },
    {
      "nct_id": "NCT00511901",
      "title": "Prevalence and Treatment of Anemia in Rehabilitation Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Anemia"
      ],
      "interventions": [
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "epoetin alpha",
          "type": "DRUG"
        },
        {
          "name": "Niferex",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Medicine and Dentistry of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2005-11",
      "completion_date": "2008-05",
      "has_results": true,
      "last_update_posted_date": "2014-01-31",
      "last_synced_at": "2026-09-07T00:55:41.358Z",
      "location_count": 2,
      "location_summary": "Cranbury, New Jersey • East Brunswick, New Jersey",
      "locations": [
        {
          "city": "Cranbury",
          "state": "New Jersey"
        },
        {
          "city": "East Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00511901"
    },
    {
      "nct_id": "NCT00267007",
      "title": "A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Peripheral Neuropathy, Chemotherapy-induced"
      ],
      "interventions": [
        {
          "name": "PROCRIT 40,000 IU QW",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2006-06",
      "completion_date": "2008-08",
      "has_results": true,
      "last_update_posted_date": "2014-06-04",
      "last_synced_at": "2026-09-07T00:55:41.358Z",
      "location_count": 28,
      "location_summary": "Mobile, Alabama • Little Rock, Arkansas • Alhambra, California + 25 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Alhambra",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00267007"
    }
  ]
}